Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2022, representing the second quarter and first six months of fiscal 2023. The request metadata identifies “2021 Q2,” but the filing itself is for September 30, 2022.
Business Context
Mesa is a multinational manufacturer and developer of life science tools and quality-control products and services. Its four reportable segments are Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The filing includes the results of Agena Bioscience, acquired October 20, 2021, which established the Clinical Genomics segment.
Key Financial Metrics
| Metric | Three Months Ended September 30, 2022 | Three Months Ended September 30, 2021 | Six Months Ended September 30, 2022 | Six Months Ended September 30, 2021 |
|---|---|---|---|---|
| Revenue | $58.7 million | $35.8 million | $109.2 million | $70.8 million |
| Gross profit | $36.4 million | $23.1 million | $67.7 million | $45.4 million |
| Gross margin | 61.9% | 64.6% | 62.0% | 64.1% |
| Operating income (loss) | $4.0 million | $4.2 million | $(0.6) million | $7.3 million |
| Operating margin | 6.8% | 11.7% | (0.5)% | 10.4% |
| Net income (loss) | $1.3 million | $3.7 million | $(0.1) million | $5.7 million |
| Diluted EPS | $0.24 | $0.70 | $(0.02) | $1.07 |
| Operating cash flow | Not separately provided | Not separately provided | $7.7 million | $14.0 million |
Revenue increased 64% year over year in the quarter and 54% for the six-month period, primarily because of the Agena acquisition. Management reported organic revenue growth of 12% for the quarter and 8% year to date. Gross margin declined by approximately three percentage points in the quarter and two percentage points year to date.
- Quarterly segment revenue: Clinical Genomics $18.4 million; Sterilization and Disinfection Control $17.0 million; Biopharmaceutical Development $12.1 million; Calibration Solutions $11.2 million.
- Year-to-date segment revenue: Clinical Genomics $32.9 million; Sterilization and Disinfection Control $31.7 million; Biopharmaceutical Development $23.1 million; Calibration Solutions $21.4 million.
- Cash and working capital: Cash was $32.4 million at September 30, 2022, compared with $49.3 million at March 31, 2022. Working capital was $74.8 million, compared with $76.3 million at March 31, 2022.
- Debt: $27.0 million was outstanding under the credit facility and $172.5 million of convertible notes principal was outstanding. The notes had a net carrying value of $169.8 million and mature August 15, 2025.
- Capital allocation: Six-month debt repayments were $22.0 million, dividends paid were $1.7 million, and capital expenditures were $1.9 million. The quarterly dividend remained $0.16 per share.
Material Changes Versus the Prior Comparable Period
- Agena materially increased reported revenue, operating expenses, amortization, and research and development costs. Six-month operating expenses increased 80%, including higher selling, general and administrative, and research and development costs.
- Despite strong revenue growth, six-month operating income declined to a loss of $0.6 million from income of $7.3 million, and net income declined to a loss of $0.1 million from income of $5.7 million.
- Gross margin pressure reflected foreign exchange impacts, inflation, supply-chain constraints, labor costs, and product mix.
- Foreign currency translation produced a $29.2 million loss in other comprehensive income for the six months, reducing accumulated other comprehensive income to a $25.5 million loss.
- Operating cash flow declined by $6.3 million year over year, primarily because of lower collections, increased inventory purchases, and other working-capital uses.
- Clinical Genomics revenue in the second quarter increased 27% from the first quarter as China-related shutdown restrictions eased. COVID-19-related sales were limited to $0.2 million in the quarter and $0.4 million for the six months.
Guidance, Outlook, Risks, and Unusual Items
- Management did not provide a specific numerical revenue or earnings outlook in the filing.
- Mesa increased prices late in the second quarter in response to inflation and expected to begin realizing those increases in the third quarter of fiscal 2023.
- Supply-chain constraints continued, particularly in Calibration Solutions. The company increased purchases of critical raw materials, contributing to higher inventory and approximately $24.3 million of open purchase orders payable within one year.
- Labor shortages and wage inflation affected all divisions, particularly Sterilization and Disinfection Control. Management added temporary and permanent manufacturing personnel at its Bozeman, Montana facility.
- Foreign exchange volatility, especially the stronger U.S. dollar against the euro, Swedish krona, and Chinese yuan, reduced reported revenue and created a $29.2 million year-to-date translation loss. Mesa does not hedge foreign exchange exposure.
- Interest-rate risk increased: the credit facility’s weighted-average borrowing rate was 4.9% at September 30, 2022, compared with 1.5% at March 31, 2022. A 75-basis-point increase would add approximately $0.2 million of annual interest expense based on the outstanding balance.
- The company stated that it was in compliance with all credit-facility covenants at September 30, 2022. In October 2022, it repaid an additional $2.0 million under the facility.
- The company believes operating cash flow, cash on hand, credit-facility availability, and potential equity issuance will be sufficient for ongoing needs. It has an Open Market Sale Agreement permitting potential issuance of up to $150 million of common stock.
- The effective tax rate was unusually volatile: 61.4% in the quarter and negative 93.5% for the six-month period, primarily due to share-based compensation and the geographic mix of earnings.
- No material legal reserves were recorded, and management reported no material changes to the risk factors in the fiscal 2022 Form 10-K.
Important Facts for Investors to Verify
- Confirm the extent to which future revenue growth is organic versus attributable to the Agena acquisition.
- Monitor whether price increases offset inflation, labor costs, supply-chain constraints, and adverse foreign exchange effects.
- Assess the integration of Agena, including amortization, stock-based compensation, operating costs, and control changes.
- Review liquidity and covenant compliance in light of $199.5 million of debt principal and the August 2025 convertible-note maturity.
- Evaluate inventory growth, open purchase commitments, receivables collection, and their effects on operating cash flow.
- Track Clinical Genomics performance in China and the potential recurrence of COVID-19-related restrictions.
- Reconcile the unusually high effective tax rate and the continuing effect of non-cash amortization and stock-based compensation on earnings.